Cytosorbents Corp (CTSO)

↓ Download CSV

CIK 0001175151 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Cytosorbents Corp reported revenue of $37.06M, up 4.1% from the prior year. The company ran a net loss, with a net margin of -22.1% and a gross margin of 71.5%. It held $44.18M in total assets against $38.28M in total liabilities.

Key ratios (FY2025)

71.5%
Gross margin
-39.8%
Operating margin
-22.1%
Net margin
-138.9%
Return on equity
+4.1%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$37.06M$35.59M$31.08M$34.69M$43.17M$41.00M$24.95M$22.50M$15.15M$8.21M
Cost of Revenue$10.57M$10.71M$9.13M$13.96M$11.05M$11.05M$7.36M$7.49M$5.52M$3.95M
Gross Profit$26.49M$24.89M$21.95M$20.73M$32.12M$29.95M$17.59M$15.01M$9.63M$5.57M
Operating Income-$14.75M-$16.45M-$31.95M-$31.52M-$22.74M-$10.37M-$18.97M-$15.58M-$9.84M-$11.49M
Net Income-$8.20M-$20.72M-$29.25M-$32.81M-$24.56M-$7.84M-$19.27M-$17.21M-$8.46M-$11.76M
EPS (Diluted)$-0.13$-0.38$-0.65$-0.75$-0.57$-0.20$-0.60
Total Assets$44.18M$47.37M$52.96M$63.23M$89.52M$89.95M$27.38M$34.20M$24.10M$9.69M
Total Liabilities$38.28M$36.27M$29.48M$27.86M$26.94M$10.73M$23.96M$17.26M$13.84M$8.36M
Shareholders' Equity$5.90M$11.11M$23.48M$35.37M$62.58M$79.22M$3.42M$16.93M$10.26M$1.34M
Cash & Equivalents$6.25M$3.28M$14.13M$22.14M$52.14M$71.42M$12.23M$22.37M$17.32M$5.25M
Operating Cash Flow-$12.38M-$14.43M-$21.66M-$28.23M-$14.01M-$5.61M-$16.76M-$10.84M-$6.46M-$6.73M
Capital Expenditures$164.0K$284.0K$538.1K$6.09M$3.64M$708.4K$698.2K$672.0K$990.7K$140.7K
Shares Outstanding62.80M54.83M54.24M43.64M43.64M43.22M32.62M31.77M28.97M25.48M